Stuart L Silverman1, Michael Maricic. 1. UCLA/Cedars-Sinai, Osteoporosis Medical Center, Beverly Hills, California 90211, USA. stuarts@omcresearch.org
Abstract
OBJECTIVE: To provide a review of current developments in bisphosphonates indicated for the treatment of several rheumatologic conditions, including postmenopausal and glucocorticoid-induced osteoporosis. METHODS: This review summarizes the pathology, diagnosis, and treatment of both postmenopausal and glucocorticoid-induced osteoporosis and examines the results of current clinical trials of the newest oral and intravenous formulations of nitrogen-containing bisphosphonates. We discuss important adverse events, including upper gastrointestinal symptoms and osteonecrosis of the jaw. Additionally, we explore methods that may improve patient adherence to bisphosphonate therapy, which is currently suboptimal. RESULTS: Clinical studies have shown that oral bisphosphonates are efficacious in increasing bone mineral density and reducing risk of fracture. Despite concerns of upper gastrointestinal irritation, most of the newer oral bisphosphonates display a safety profile similar to placebo. Many of the newest formulations offer patients a choice in both dosing frequency and method of administration (either oral or intravenous). CONCLUSIONS: Nitrogen-containing bisphosphonates are important therapeutic options for the prevention and treatment of osteoporosis.
OBJECTIVE: To provide a review of current developments in bisphosphonates indicated for the treatment of several rheumatologic conditions, including postmenopausal and glucocorticoid-induced osteoporosis. METHODS: This review summarizes the pathology, diagnosis, and treatment of both postmenopausal and glucocorticoid-induced osteoporosis and examines the results of current clinical trials of the newest oral and intravenous formulations of nitrogen-containing bisphosphonates. We discuss important adverse events, including upper gastrointestinal symptoms and osteonecrosis of the jaw. Additionally, we explore methods that may improve patient adherence to bisphosphonate therapy, which is currently suboptimal. RESULTS: Clinical studies have shown that oral bisphosphonates are efficacious in increasing bone mineral density and reducing risk of fracture. Despite concerns of upper gastrointestinal irritation, most of the newer oral bisphosphonates display a safety profile similar to placebo. Many of the newest formulations offer patients a choice in both dosing frequency and method of administration (either oral or intravenous). CONCLUSIONS:Nitrogen-containing bisphosphonates are important therapeutic options for the prevention and treatment of osteoporosis.
Authors: Wei Liu; Asghar Hajibeigi; Mai Lin; Cynthia L Rostollan; Zoltan Kovacs; Orhan K Oz; Xiankai Sun Journal: Bioorg Med Chem Lett Date: 2008-07-27 Impact factor: 2.823
Authors: L Lo Russo; D Ciavarella; C Buccelli; O Di Fede; G Campisi; L Lo Muzio; G Pellegrino; P Di Lorenzo Journal: Br Dent J Date: 2014-09 Impact factor: 1.626
Authors: A Barasch; J Cunha-Cruz; F A Curro; P Hujoel; A H Sung; D Vena; A E Voinea-Griffin; Steven Beadnell; Ronald G Craig; Timothy DeRouen; Ananda Desaranayake; Ann Gilbert; Gregg H Gilbert; Ken Goldberg; Richard Hauley; Mariko Hashimoto; Jon Holmes; Brooke Latzke; Brian Leroux; Anne Lindblad; Joshua Richman; Monika Safford; Jonathan Ship; Van P Thompson; O Dale Williams; Wanrong Yin Journal: J Dent Res Date: 2011-02-11 Impact factor: 6.116
Authors: Francisco Javier Manzano-Moreno; Javier Ramos-Torrecillas; Elvira De Luna-Bertos; Candela Reyes-Botella; Concepción Ruiz; Olga García-Martínez Journal: Clin Oral Investig Date: 2014-08-28 Impact factor: 3.573